


Within world-class GLP facilities, TetraQ ADME offers a range of *in vitro* and *in vivo* services for the analysis of drugs and metabolites in biological fluids. We also frequently analyse samples generated from externally conducted studies including early Phase clinical studies. We are recognised as leaders in the development of validated assays for drugs and metabolites and use the latest equipment. We take pride in having highly interactive relationships with our clients and work seamlessly with the other areas of TetraQ to provide a complete solution.

### Analytical Services

- Method development for drugs in biological fluids using LC-MS/MS (4000-QTrap), HPLC, etc.
- Full validation of methods to regulatory requirements, or reduced level of validation as appropriate
- Analysis of samples generated from studies conducted in-house (including from efficacy or toxicology studies) or contract analysis of samples from external sources such as clinical trials
- Three Applied Biosystems LCMSMS instruments- API4000, QTrap 4000 and API3200 with a fourth instrument to be purchased in Q1, 2011
- Online LCMSMS Spark SPE robotics for rapid bioanalysis
- Validated assays for >130 compounds on hand
- ELISA Assay
  - Transferred and conducted partial validation of ELISA assay for major Australian biotech organisation with analysis of 1500 plasma samples



### Consulting

In addition to providing a range of contract services for clients, we are available to consult to your business and advise on early stage drug development activities. This may include participation in meetings of scientific advisory boards, providing an expert opinion, or reviewing documentation.

**Absorption**  
**Distribution**  
**Metabolism**  
**Elimination**



TetraQ-ADME is GLP recognised and is accredited with NATA in the field of Research and Development, and operates in accordance with ISO/IEC 17025 (2005)

### *in vivo* ADME Services

TetraQ conducts a range of studies in rats and mice (other species are possible), including:

- Pharmacokinetics including dosing *via* i.v., oral, subcutaneous, intraperitoneal or intramuscular routes
- Calculation of basic PK parameters
- Bioavailability following dosing by any of these routes
- Metabolism studies, including metabolite identification (mass spectral and/or after enzymatic incubations)
- Recovery of parent drug and/or metabolites in urine, faeces or bile
- Tissue distribution studies, including dosing with non-radiolabelled or radiolabelled (supplied by the Sponsor) versions of the investigational drug

### *in vitro* ADME Services

TetraQ conducts *in vitro* screening including:

- Metabolic stability screening or profiling due to Phase I (CYP450) or Phase II (glucuronidation / sulfonation) processes
- Studies conducted using cryopreserved hepatocytes (pooled human or male or female animal), microsomes or S9 as appropriate

**Key Contact - Business Development Manager:**  
Otto Damsma +61 7 3346 9933  
o.damsma@tetraq.com.au